中文Recently, BioGeometry, a digital biology pioneer company that specializes in applying generative AI to protein design, and BioMetas jointly announced the signing of a strategic cooperation agreement in the field of AI-driven large molecule pharmaceuticals. The two parties will engage in deep collaboration on platform products, project optimization services, and resource expansion to promote innovation together in antibody research and development, providing pharmaceutical clients with higher-quality R&D services.
Under the terms of the agreement, BioGeometry will provide BioMetas with access to its advanced antibody discovery models or the generative AI antibody design platform (GeoBiologics), which BioMetas will utilize to train and optimize with project data. BioGeometry will offer specialized services such as antibody humanization, druglikeness analysis, and affinity analysis based on the specific needs of each project. Both parties will also actively recommend each other’s resources, working together to create a more comprehensive new drug R&D service, and drive deeper development of the business ecosystem.
Dr. Yingjia Zhang, founder and president of BioMetas, stated: “BioGeometry has gathered a top team of experts in the AI field and has achieved various breakthroughs in large molecule drug discovery and design. We believe that with the support of BioGeometry’s GeoBiologics antibody design platform, BioMetas’s one-stop preclinical biopharmaceutical R&D service capabilities can reach new heights, providing pharmaceutical clients with higher quality, more efficient, and cost-effective R&D solutions.”
” BioMetas is a global leader in CRO,” said Dr. Jian Tang, founder and CEO of BioGeometry: “Combining our technological strengths in generative AI antibody discovery, and through virtual screening, we aim to improve the success rate of modifications and reduce R&D costs and timelines, providing more efficient and higher quality large molecule drug development solutions to our clients in the pharmaceutical industry, and exploring more possibilities for industry development.”
About BioGeometry
BioGeometry an AI-driven biotech company dedicated to understanding the language of life through generative AI (AIGC), reconstructing the protein drug discovery and design process, and creating programmable proteins. It solves issues related to the traditionally high costs, long cycles, low success rates, and difficult drug targets in large molecule pharmaceuticals, providing innovative drugs to save patients’ lives. Founded in 2022 by Dr. Jian Tang, a renowned scientist in AI4Drug and deep learning on graphs, with Turing Award laureate Yoshua Bengio serving as the chief scientific advisor, the company has built two foundational platforms: an AI-driven large molecule drug design platform and high-throughput wet-lab validation, creating a closed-loop system that empowers partners to achieve precise and efficient large molecule drug design and optimization.
Business Cooperation: bd@biogeom.com
Official Website: www.biogeom.com
About BioMetas
BioMetas headquartered in Shanghai is a culmination of decades of experience in novel drug development services, providing solutions to major pharmaceutical companies and biotech’s alike, including target validation, molecular biology, protein expression and purification, antibody expression and purification, in vitro drug screening, cell-level drug screening, in vivo pharmacology and efficacy, pharmacokinetics and pharmacodynamics, bioanalysis, and up to preclinical candidate drug discovery and IND filing for both China and the United States.
Business Cooperation: Info@biometasgroup.com
Official Website: www.biometasgroup.com